|
Report Date : |
19.12.2014 |
IDENTIFICATION DETAILS
|
Name : |
JUPITER BIOSCIENCE AG |
|
|
|
|
Registered Office : |
Alte Hauensteinstrases 4, 4448 Läufelfingen/BL |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
03.03.2008 |
|
|
|
|
Com. Reg. No.: |
280.3.011.515-4 / 901798 |
|
|
|
|
Legal Form : |
Company limited by shares |
|
|
|
|
Line of Business : |
Subject is engaged in development, manufacture and distribution of chemical substances, in particular with syntheses of peptides and other specialty and fine chemicals, pharmaceutical intermediates, bulk drugs and nutraceuticals |
|
|
|
|
No of Employees : |
14 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
Switzerland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
SWITZERLAND ECONOMIC OVERVIEW
Switzerland is a peaceful, prosperous, and modern market economy with low unemployment, a highly skilled labor force, and a per capita GDP among the highest in the world. Switzerland's economy benefits from a highly developed service sector, led by financial services, and a manufacturing industry that specializes in high-technology, knowledge-based production. Its economic and political stability, transparent legal system, exceptional infrastructure, efficient capital markets, and low corporate tax rates also make Switzerland one of the world's most competitive economies. The Swiss have brought their economic practices largely into conformity with the EU's to enhance their international competitiveness, but some trade protectionism remains, particularly for its small agricultural sector. The fate of the Swiss economy is tightly linked to that of its neighbors in the euro zone, which purchases half of all Swiss exports. The global financial crisis of 2008 and resulting economic downturn in 2009 stalled export demand and put Switzerland in a recession. The Swiss National Bank (SNB) during this period effectively implemented a zero-interest rate policy to boost the economy as well as prevent appreciation of the franc, and Switzerland's economy began to recover in 2010. The sovereign debt crises currently unfolding in neighboring euro-zone countries pose a significant risk to Switzerland's financial stability and are driving up demand for the Swiss franc by investors seeking a safe-haven currency. The independent SNB has upheld its zero-interest rate policy and conducted major market interventions to prevent further appreciation of the Swiss franc, but parliamentarians have urged it to do more to weaken the currency. The franc's strength has made Swiss exports less competitive and weakened the country's growth outlook; GDP growth fell below 2% per year during 2011-13. Switzerland has also come under increasing pressure from individual neighboring countries, the EU, the US, and international institutions to reform its banking secrecy laws. Consequently, the government agreed to conform to OECD regulations on administrative assistance in tax matters, including tax evasion. The government has renegotiated its double taxation agreements with numerous countries, including the US, to incorporate the OECD standard, and is considering the possibility of imposing taxes on bank deposits held by foreigners. These steps will have a lasting impact on Switzerland's long history of bank secrecy.
|
Source
: CIA |
Jupiter Bioscience
AG
Alte
Hauensteinstrases 4
4448
Läufelfingen/BL
Switzerland/CH
Telephone: 062
2852060
Fax: 062
2852061
Web
site: http://www.jupiterbioscience.ch
E-mail: info@jupiterbioscience.ch
WIN
Worldbox No.: CH0007806179
VAT-No.: CHE114112077
Established: 2008
Line
of Business: Chemicals,
Pharmaceutics
Industry
Division: Manufacturing, Services
Industry-code (NACE): 2059 Manufacture of other chemical products
n.e.c.
2110 Manufacture of basic pharmaceutical
products
7219 Other research and experimental
development on natural sciences and engineering
Import/Export: Import, Export
Quality
certification: ISO 9001:2000
Banks: unknown
Coverage: Company
Figures: estimated
Financial
year: 2014
Employees: 14
Sales: CHF 7,500,000.--
The business comprises the development,
manufacture and distribution of chemical substances, in particular with
syntheses of peptides and other specialty and fine chemicals, pharmaceutical
intermediates, bulk drugs and nutraceuticals. The customers of the products
include pharmaceutical and biotechnology industries worldwide.
Information on property ownership was not
available.
Company
No: 280.3.011.515-4 / 901798
Legal
form: Company limited by
shares
Registration: 03.03.2008
Legal
status: active
Responsible
Register: Handelsregister des Kantons Basel-Landschaft
History: Date of Incorporation
Statutes: 22.02.2008
Entry Deleted Name
03.03.2008 Jupiter
Bioscience AG
Entry Deleted Legal domicile
03.03.2008 Läufelfingen,
Switzerland
Entry Deleted Address
03.03.2008 Alte
Hauensteinstrases 4, 4448 Läufelfingen/BL, Switzerland/CH
Entry Deleted Capital
03.03.2008 Share
Capital CHF 100,000, paidup CHF 100,000
Entry Deleted Capital Structure
03.03.2008 1,000
Bearer shares of CHF 100.--
Title Name
President Venkat
Ramana Kalavakolanu
Citizen:
India
Residential
address: Secunderabad / Andhra Pradesh, India
single
signature
Registered
since: 03.03.2008
Owner: The company is
privately owned.
It is believed that the company has no
investments.
Control date Year No. Amount CHF Status
23.03.2012 2012 0
31.12.2011 2011 0
31.12.2010 2010 0
An updated legal action check is only
available against proof of interest. e.g. a copy of an enquiry letter, and order
or invoice relating to the subject company.
Financial
Statements: The company does not
disclose any financial statements. Third parties are not permitted any insight
into the financial affairs. It is therefore difficult to make a proper
assessment of the actual situation.
Financial
Situation: The financial situation
is difficult to assess.
Payment
experiences: There are no objections
regarding the payment of financial obligations.
Credit
Opinion: In advancing credit
it is advised that a bank guarantee be obtained.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 63.31 |
|
|
1 |
Rs. 98.67 |
|
Euro |
1 |
Rs. 78.10 |
INFORMATION DETAILS
|
Analysis Done by
: |
SUB |
|
|
|
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.